- Trials with a EudraCT protocol (10,853)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
10,853 result(s) found for: Contraception.
Displaying page 330 of 543.
EudraCT Number: 2007-002581-35 | Sponsor Protocol Number: CL-033-II-02 | Start Date*: 2007-09-25 | |||||||||||
Sponsor Name:IDEA AG | |||||||||||||
Full Title: Multiple dose, double-blind, double-dummy, placebo and active controlled study of pharmacokinetics of Diractin® as well as safety and efficacy for the treatment of muscle soreness from exercise | |||||||||||||
Medical condition: The study population is a healthy population who are voluntarily participating in this clinical trial. This study will compare the PK profile after e.c. and oral application of the same dosage of ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004640-21 | Sponsor Protocol Number: CT327-2003 | Start Date*: 2012-02-13 | |||||||||||
Sponsor Name:Creabilis Limited | |||||||||||||
Full Title: A Randomized, Placebo-controlled Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w topical CT327 when Applied Twice Daily in Subjects with Psoriasis Vulg... | |||||||||||||
Medical condition: Psoriasis Vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000879-14 | Sponsor Protocol Number: CT/11.01 | Start Date*: 2011-06-06 |
Sponsor Name:Hellenic Oncology Research Group (H.O.R.G.) | ||
Full Title: A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC). | ||
Medical condition: Relapsed and Refractory Small Cell Lung Cancer | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018334-51 | Sponsor Protocol Number: POX-MVA-032 | Start Date*: 2010-07-15 | ||||||||||||||||
Sponsor Name:Bavarian Nordic A/S | ||||||||||||||||||
Full Title: An open-label, non-controlled study to immunize healthy volunteers actively working with or in the vicinity of replicating Vaccinia virus with IMVAMUNE® (MVA-BN®) | ||||||||||||||||||
Medical condition: Healthy subjects actively working with or in the vicinity of replicating Vaccinia virus will receive immunization IMVAMUNE to offer protection against accidential Vaccinia virus infection. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002378-30 | Sponsor Protocol Number: CPN710102 | Start Date*: 2012-08-23 |
Sponsor Name:CellAct Pharma GmbH | ||
Full Title: Phase II Trial of CAP7.1 in adult patients with refractory malignancies Small cell lung carcinoma, Non-small cell lung carcinoma Biliary carcinoma | ||
Medical condition: Treatment of Therapy refractory none small cell lung Cancer (NSCLC), small cell lung Cancer (SCLC) and Biliary carcinoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-019121-34 | Sponsor Protocol Number: E-3810-I-01 | Start Date*: 2011-03-28 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics, and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase ... | |||||||||||||
Medical condition: Dose escalation: solid tumors failing standard therapy. Dose-expansion: solid tumors A) with FGFR1 amplification and for breast cancer ? 1 prior endocrine therapy if ER+ or ? 1 chemotherapy otherwi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013422-17 | Sponsor Protocol Number: CHUBX2009/09 | Start Date*: 2009-12-29 | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Etude de l’efficacité et de la toxicité d’une stratégie d’allogreffe de cellules souches hématopoïétiques à conditionnement atténué dans le lymphome folliculaire en rechute chimiosensible. | |||||||||||||
Medical condition: Follicular lymphoma Allogeneic hematopoietic stem cell transplantation Reduced-intensity conditioning | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024000-10 | Sponsor Protocol Number: 101MS206 | Start Date*: 2011-06-28 | |||||||||||
Sponsor Name:Biogen Idec Limited | |||||||||||||
Full Title: A Randomized, Blinded, Parallel-Group, Phase 2 Study Exploring the Safety, Tolerability, and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing-Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005169-78 | Sponsor Protocol Number: P080301 | Start Date*: 2009-02-23 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Traitement des récidives de glioblastomes par le SUTENT (SU11248) : essai de phase 2 avec étude translationnelle biologique et en imagerie | |||||||||||||
Medical condition: Patients atteints de glioblastomes en récidive | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019369-27 | Sponsor Protocol Number: ANX001-01 | Start Date*: 2010-07-23 | |||||||||||
Sponsor Name:Anxiofit Ltd. | |||||||||||||
Full Title: A Phase II randomized, double-blind, parallel-group, multi-site, placebo controlled fixed-dose study of Echinaceae angustifoliae root dry extract in 24 outpatients with generalized anxiety disorder... | |||||||||||||
Medical condition: Generalized Anxiety Disorder (GAD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004847-61 | Sponsor Protocol Number: 008717QM | Start Date*: 2013-01-16 | |||||||||||
Sponsor Name:Queen Mary University of London | |||||||||||||
Full Title: A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhan... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002348-28 | Sponsor Protocol Number: 0462-083 | Start Date*: 2011-06-30 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Single-Dose Pharmacokinetics of MK-0462 in Migraineurs Aged 6 to 17 Years | |||||||||||||
Medical condition: Migraine | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018875-30 | Sponsor Protocol Number: BRD10/1-P | Start Date*: 2010-04-06 | |||||||||||
Sponsor Name:CHU de Nantes | |||||||||||||
Full Title: Comparaison de l’effet antisécrétoire d’une dose unique de rabeprazole 20 mg et d’omeprazole 20 mg chez des sujets obèses | |||||||||||||
Medical condition: reflus gastro-oesophagien | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020202-16 | Sponsor Protocol Number: FC-002 | Start Date*: 2010-11-19 | |||||||||||
Sponsor Name:ProFibrix BV | |||||||||||||
Full Title: A Phase 2, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety and Study of Topical Fibrocaps™ and Gelatin Sponge (USP) in Surgical Hemostasis in the Netherlands | |||||||||||||
Medical condition: Hepatic resection or soft tissue dissection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2009-016732-12 | Sponsor Protocol Number: MAP0004-CL-P203 | Start Date*: 2010-01-21 | |||||||||||
Sponsor Name:MAP Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by Oral Inhalation (MAP0004... | |||||||||||||
Medical condition: migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021639-15 | Sponsor Protocol Number: GC1008 | Start Date*: 2011-07-07 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Guiding GC1008 treatment of primary brain tumors by 89Zr-GC1008 PET imaging. | ||
Medical condition: High grade malignant glioma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004200-38 | Sponsor Protocol Number: N11RFA | Start Date*: 2012-03-28 | ||||||||||||||||
Sponsor Name:NKI-AVL | ||||||||||||||||||
Full Title: Phase II study exploring safety and efficacy of the combination of ipilimumab with radiofrequency ablation (RFA) in patients with unresectable uveal melanoma liver metastasis (SECIRA-UM) | ||||||||||||||||||
Medical condition: Unresectable uveal melanoma liver metastasis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000284-40 | Sponsor Protocol Number: 3/001/14 | Start Date*: 2014-06-05 | |||||||||||
Sponsor Name:University of Aberdeen [...] | |||||||||||||
Full Title: An open label investigation of the tolerability and pharmacokinetics of oral cysteamine in adults with Cystic Fibrosis. | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006115-59 | Sponsor Protocol Number: GNM-2011 | Start Date*: 2012-06-11 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: "A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)" | |||||||||||||
Medical condition: MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-006168-30 | Sponsor Protocol Number: RLH_Pentoxifylline_Dec2011 | Start Date*: 2013-01-08 | |||||||||||
Sponsor Name:R&D, Barts and The London NHS Trust | |||||||||||||
Full Title: PEntoxifylline in Anaemia Resistant to erythropoietin (PEAR) | |||||||||||||
Medical condition: We shall study patients with renal failure on dialysis. We shall particularly focus on patients with evidence of erythopoeitin stimulating agent (ESA) resistance. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
